Skip to content

Acute Heart Graft Rejection Screening by Cardiac Magnetic Resonance Imaging

Acute Heart Graft Rejection Screening by Cardiac Magnetic Resonance Imaging

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02400840
Acronym
DRAGON
Enrollment
0
Registered
2015-03-27
Start date
2015-01-31
Completion date
2018-05-31
Last updated
2016-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Graft

Brief summary

Acute heart allograft rejection is a common complication after orthotopic heart transplantation. Primary objective of this study is to assess cardiac MRI as a tool for acute heart graft rejection screening, by detecting changes in myocardium structure especially extracellular volume.

Detailed description

Acute heart allograft rejection is a common complication after orthotopic heart transplantation. It can lead to multiple cardiac injuries and sometimes to patient's death. Currently, acute heart graft rejection screening is based on invasive strategies. Gold standard is represented by endomyocardial biopsies which provide side effects risk, rare but potentially fatal for the recipient. Cardiac MRI is an imaging tool recently used in cardiology. It is a non-invasive without any X-Ray exposition method well adapted to assess cardiac function and cardiac muscle composition. Cardiac MRI is probably a great tool to help the screening of acute heart allograft rejection, by detecting changes in myocardium structure. MRI validation as a screening tool for heart allograft rejection detection could help to reduce endomyocardial biopsies realised after orthotopic heart transplantation.

Interventions

PROCEDUREcardiac MRI

Cardiac MRI is done using gadobenic acid intravenous injection 0.2 ml/kg one time

DRUGgadobenic acid intravenous injection 0.2 ml/kg

gadobenic acid intravenous injection 0.2 ml/kg is used one time for cardiac MRI assessment

Sponsors

University Hospital, Rouen
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Orthotopic heart transplantation patients * Endomyocardial biopsies \< 72h * Estimated glomerular filtration ratio \>30ml/min (calculated by Cockcroft formula for patients age \< 65 yo or MDRD for patients age \>65 ans) * Patients affiliated to French national health insurance * For pre-menopausal female patients, negative pregnancy test * Patient's consent form signature * Patient with correct French writing and speaking comprehension

Exclusion criteria

* Endomyocardial biopsies showing acute cellular rejection grade 1R or antibodies mediated rejection pAMR1 * Patient in need of renal dialysis * Past history of allergic reaction or side effects after gadolinium infusion * Hemodynamical instability * MRI contra-indication (claustrophobia, ocular metallic objects, non MRI compatible cardiac device, neurological non RMI compatible device, osteosynthesis prosthesis older than 1980) * Pregnant or breast feeding woman * Patient participating to another clinical trial

Design outcomes

Primary

MeasureTime frame
Number of patient with an acute rejection detected using Cardiac MRI after orthotopic heart transplantationDay 1

Secondary

MeasureTime frame
Extracellular volume as measured by Cardiac MRIDay 1
T1 as measured by Cardiac MRIDay 1
T2 as measured by Cardiac MRIDay 1

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026